Brief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
BRIEF-Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics June 15 (Reuters) - Sensei Biotherapeutics Inc SNSE.O:
SENSEI BIOTHERAPEUTICS ANNOUNCES NAME CHANGE TO FAETH THERAPEUTICS, FOCUSED ON ADVANCING PIKTOR, AN ORAL THERAPY TARGETING ONE OF THE MOST FREQUENTLY ALTERED PATHWAYS IN CANCER
SENSEI BIOTHERAPEUTICS - COMMON STOCK TO BEGIN TRADING AS FTH ON NASDAQ ON JUNE 16, 2026
SENSEI BIOTHERAPEUTICS - APPOINTS ANAND PARIKH AS CHAIRMAN, PRESIDENT AND CEO EFFECTIVE JUNE 12, 2026
SENSEI BIOTHERAPEUTICS - APPOINTS BRIAN STEPHENSON AS CHIEF FINANCIAL OFFICER
SENSEI BIOTHERAPEUTICS - PIKTOR PHASE 2 TOPLINE DATA IN ADVANCED ENDOMETRIAL CANCER EXPECTED SECOND HALF 2026
SENSEI BIOTHERAPEUTICS - PIKTOR PHASE 1B/2 INTERIM DATA IN HR+/HER2- ADVANCED BREAST CANCER EXPECTED IN 2027
Source text: ID:nBw48Dc9ra
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)